Search

Displaying results 1401 - 1410 of 8170 in total
  1. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    Male hypogonadism, resulting from insufficient testosterone secretion, can result symptoms and signs of testosterone deficiency, such as decreased libido, erectile dysfunction, and loss of muscle and bone

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Zimlovisertib

    go.drugbank.com/drugs/DB15143
    Investigational

    PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).

  3. Drug

    PF-05089771

    go.drugbank.com/drugs/DB14856
    Investigational

    PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).

  4. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.

  5. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

    Synonyms: 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purineCategories: P-glycoprotein substrates
  6. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  7. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    [L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Ran-finasteride, Van-finasteride
  8. Drug

    PF-04457845

    go.drugbank.com/drugs/DB12012
    Investigational

    PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.

  9. Drug

    Iohexol

    go.drugbank.com/drugs/DB01362
    ApprovedInvestigational

    Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

  10. Drug

    Fenofibrate

    go.drugbank.com/drugs/DB01039
    ApprovedInvestigational

    Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. Fenofibrate was granted FDA approval on 31 December 1993.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate